India Glycols Limited Reports ₹358.18 Crore Q2 FY27 Revenue
Key highlights
- India Glycols reported standalone Q2 FY27 revenue from operations of ₹358.18 crore.
- Standalone Q2 FY27 EBITDA was ₹39.34 crore, compared with ₹40.21 crore in Q1 FY27.
- Standalone Q2 FY27 PAT was ₹11.24 crore and quarterly EPS was ₹1.68.
- Consolidated Q2 FY27 revenue was ₹362.42 crore and consolidated net profit was ₹23.69 crore.
powered by IRIS

India Glycols Limited reported standalone revenue from operations of ₹358.18 crore and EBITDA of ₹39.34 crore for Q2 FY27, its first reported quarter after the Scheme of Arrangement. The results cover the continuing operations, while prior-year figures include demerged businesses and are therefore not directly comparable.
Know India Glycols inside out
Results, valuation, peers and who's buying, in one view.
What did India Glycols report for Q2 FY27?
India Glycols reported unaudited standalone revenue from operations of ₹358.18 crore for the quarter ended September 30, 2026. Standalone EBITDA was ₹39.34 crore, while profit after tax stood at ₹11.24 crore and quarterly earnings per share were ₹1.68.
The company disclosed the results on November 17, 2026, after its Board approved the standalone and consolidated financial statements for the quarter and half year ended September 30. The standalone numbers relate only to the company’s continuing operations following the Scheme of Arrangement, comprising Biobased Specialty Materials and Sustainable & Performance Chemicals, Gases.
On a sequential standalone basis, revenue increased by ₹3.54 crore from ₹354.64 crore in Q1 FY27. EBITDA declined by ₹0.87 crore and PAT decreased by ₹1.11 crore from the preceding quarter. The reported standalone EBITDA margin was about 11.0% of revenue.
Why are the Q2 FY26 comparisons not directly comparable?
The Q2 FY26 standalone figures included businesses that have since been demerged under the Scheme of Arrangement, India Glycols said. As a result, the reported comparison of revenue falling from ₹2,410.71 crore in Q2 FY26 to ₹358.18 crore in Q2 FY27 does not represent a like-for-like change in the continuing business.
The same qualification applies to EBITDA and PAT. The Q2 FY26 EBITDA of ₹160.25 crore and PAT of ₹53.94 crore were recorded before the revised business structure, whereas the latest quarter covers only the retained operating segments. Investors assessing the performance of the continuing operations therefore need to distinguish reported year-on-year movements from underlying operating trends.
The company’s disclosure frames Q2 FY27 as its first financial result after the arrangement. This makes the quarter an initial reference point for the retained business rather than a direct continuation of the historical consolidated operating profile reflected in the older reported figures.
How did the consolidated Q2 FY27 performance compare?
India Glycols reported consolidated revenue of ₹362.42 crore for Q2 FY27, with consolidated net profit of ₹23.69 crore. Consolidated revenue was stated to be 1.5% higher quarter-on-quarter, while consolidated net profit declined 27.3% from Q1 FY27.
Consolidated EBITDA was ₹35.14 crore, translating to an EBITDA margin of 9.7%. The difference between standalone and consolidated figures reflects the group-level reporting perimeter. The company also reported that its statutory auditors issued unmodified limited-review conclusions and that no exceptional item was reported for the quarter.
The quarterly outcome indicates that revenue was broadly stable sequentially on both reported bases, but profitability was lower than in the prior quarter. For the standalone business, the movement from ₹40.21 crore of EBITDA in Q1 FY27 to ₹39.34 crore in Q2 FY27 was limited, whereas PAT moved from ₹12.35 crore to ₹11.24 crore.
Got a follow-up? Ask IRIS
What does the result mean for investors and operations?
For investors, the principal issue is comparability after the Scheme of Arrangement. The substantially lower reported year-on-year standalone revenue and profit figures largely reflect the altered business perimeter disclosed by the company, rather than a directly comparable change across an unchanged set of operations.
The retained operations include biobased specialty materials and sustainable and performance chemicals and gases. The Q2 result provides the first quarterly reported financial base for these continuing businesses under the post-arrangement structure. Revenue of ₹358.18 crore and EBITDA of ₹39.34 crore establish the scale and operating earnings reported for this perimeter.
The results were released amid broader attention on profitability and demand conditions in the chemicals sector. However, the company’s disclosure does not provide a quantified breakdown of volume, pricing, input costs, or segment-level drivers for the quarter. Accordingly, the reported figures support an assessment of financial outcomes, but not a definitive attribution of the changes to individual market factors.
What disclosures and events should shareholders track next?
India Glycols scheduled an earnings conference call for November 18, 2026, at 4:00 pm IST to discuss the Q2 and H1 FY27 results. The announced participants included Chief Executive Officer Rupark Sarswat, Chief Financial Officer Anand Singhal, Head of Legal Ankur Jain, and Investor Relations head Gagan Kwatra.
The call is relevant because investors may seek additional clarity on the continuing operations, the financial effects of the Scheme of Arrangement, and the basis for evaluating quarterly performance after the demerger. The disclosed results themselves do not provide forward guidance or a forecast for future revenue, margins, or earnings.
Future quarterly filings will also provide a longer operating record for the retained businesses. With only the first reported post-scheme quarter available in the provided disclosure, sequential trends in revenue, EBITDA, PAT, margins, and the relationship between standalone and consolidated performance remain key reported measures to monitor.
Conclusion
India Glycols Limited’s Q2 FY27 results set out the first reported financial position of its continuing operations after the Scheme of Arrangement. The company recorded standalone revenue of ₹358.18 crore, EBITDA of ₹39.34 crore, and PAT of ₹11.24 crore, while stating that comparisons with Q2 FY26 are not directly comparable because prior figures included demerged businesses.
The immediate item to watch is management’s discussion at the November 18 earnings call, particularly any further explanation of the post-scheme operating structure and quarterly performance. Subsequent financial results will show whether the retained operations maintain revenue and profitability trends from this initial reporting base.


